Skip to main content

Market Overview

An Abbott Labs Analyst's 5 Reasons To Own The Stock: 'Near-Perfect For This Environment'

An Abbott Labs Analyst's 5 Reasons To Own The Stock: 'Near-Perfect For This Environment'

Health care company Abbott Laboratories (NYSE: ABT) has had a strong start to the year with forecast-beating first-quarter results and in-line full-year guidance.

The Analyst

Raymond James analyst Jayson Bedford maintained an Outperform rating on Abbott with a $79 price target.

The Thesis

Abbott shares are likely to outperform, and there are far more reasons to own the stock than not, Bedford said in a Wednesday note. (See his track record here.)

Abbott has an above-average growth profile, with 7-percent top-line growth and over 15-percent EPS growth, excluding forex, the analyst said. This is one of the most attractive profiles in the health care group, he said. 

The Illinois company has four key product-line drivers, Bedford said: Mitraclip, Libre, Heartmate 3 and Alinity/Core Lab. Together, they accounted for 23 percent of first-quarter sales. The analyst said he expects these products to sustain the 17-percent growth witnessed in the first quarter.

Abbott is well-diversified, with only 37 percent of its revenue coming from the U.S., Bedford said. 

The portfolio is diversified as well, with 24 percent of revenue coming from nutrition and 13 percent from branded generics, the analyst said. 

Raymond James noted that Abbott has been consistently meeting and exceeding consensus estimates in each of the past 21 quarters.

These positives more than offset twin negatives, Bedford said: premium valuation and perceived macro issues facing the health care sector.

" ... As the dust settles ... we expect the stock to outperform." 

Raymond James raised its 2019 estimates for Abbott slightly on the basis of the first-quarter print and strong second-quarter guidance of 7-percent organic growth and adjusted EPS of 79-81 cents.  

Abbott shares were trading up 0.48 percent to $73.21 at the time of publication Thursday. 

Related Links:

Mustang Bio Gallops Higher On Positive Gene Therapy Results For Deadly 'Bubble Boy Disease'

The Daily Biotech Pulse: Hookipa To Debut, Mustang Bio Skyrockets, AngioDynamics Sheds Portfolio

Public domain photo via Wikimedia. 

Latest Ratings for ABT

Jan 2021Cowen & Co.MaintainsOutperform
Jan 2021Credit SuisseMaintainsOutperform
Jan 2021Morgan StanleyMaintainsOverweight

View More Analyst Ratings for ABT
View the Latest Analyst Ratings


Related Articles (ABT)

View Comments and Join the Discussion!

Posted-In: Jayson BedfordAnalyst Color Earnings News Guidance Price Target Reiteration Analyst Ratings Best of Benzinga

Latest Ratings

FIXXStifelInitiates Coverage On14.0
GMTXGoldman SachsInitiates Coverage On20.0
FULCStifelInitiates Coverage On18.0
FRLNStifelInitiates Coverage On21.0
DARPiper SandlerInitiates Coverage On95.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at